Fig. 1.

WDR5 associates with malignant features and is a potential therapy target in bladder cancer. a. WDR5 expression was detected in NAT and compared with BCa tissues in the TCGA cohort. b-d. WDR5 expression was detected between low grade and high grade (b), no distant metastasis (M0) and distant metastasis (M1) (c), papillary and non-papillary (d) BCa tumour tissues in TCGA cohort. e. WDR5 expression was detected in five molecular subtypes, including luminal infiltrated, luminal papillary, luminal, basal squamous and neuronal in TCGA cohort. f. Kaplan-Meier curves for OS in BCa patients with high vs. low expression of WDR5 in the TCGA cohort. g-i. Dose-reponse curves of T24 (g), UM-UC-3 (h), and TCCSUP (i) BCa cells treated with increasing concentrations of WDR5 inhibitor (OICR-9429) for 48 h. Cellular viability was determined by MTT assay, and the IC₅₀ values were calculated based on nonlinear regression analysis. We used 70 μM as the IC₅₀ dose for T24 and UM-UC-3 cells and 120 μM as the IC₅₀ dose for TCCSUP cells. j. Western blots of H3K4me3, H3, and WDR5 protein levels in OICR-9429-treated BCa cells